secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001023024-25-000081
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma Q2 record revenues $211.4M, EPS $0.36; lifts FY guidance
-------------------------------------------------------------------

- Q2 net revenue $211.4M (+53.1% YoY); GAAP EPS $0.36 vs ($0.14); record adjusted EBITDA $54.1M (+62.8%).
- Rare Disease rev $104.0M (Cortrophin Gel $81.6M, +66%; ILUVIEN/YUTIQ $22.3M).
- Generics rev $90.3M (+22.1%); driven by new launches including first-to-market prucalopride.
- Raised FY2025 guidance: rev $818M–$843M; adj EBITDA $213M–$223M; adj EPS $6.98–$7.35.
- Cash & equivalents $217.8M; year-to-date CFO $110.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000081/0001023024-25-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000081/ani-20250808.htm
  HTML page:      https://secwatch.observer/filing/0001023024-25-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer